Tag: options

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”

Quickwork's new on-premises, virtual private cloud (VPC), and air-gapped deployment capabilities enable enterprises to run integration, automation, and AI workflows entirely within their own controlled infrastructure environments.

La Hulpe, Belgium - 15 June 2026, 7:00 a.m. CET – INSIDE INFORMATION - Banqup Group SA (Euronext Brussels: BANQ) (“Banqup” or the “Company”) today announces that, following an extensive review, the Board has approved a strategic simplification plan to reorganize the Group into distinct, autonomous business units to enhance operational focus and transparency. Lazard is mandated to explore all strategic options, including the sale of individual business units or the Group as a whole in order to maximize stakeholder value.

ROCKVILLE, Md. and SUZHOU, China, June 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel therapies to address unmet medical needs in cancer, announced today that seventeen clinical updates from its core assets were presented at the 31^st Congress of the European Hematology Association (EHA2026), including eight poster presentations. The presentations featured data from ongoing clinical studies of olverembatinib (HQP1351), the first third-generation BCR-ABL1 inhibitor approved in China, and lisaftoclax (APG-2575), the first approved China-developed Bcl-2 selective inhibitor. The EHA2026 Congress convened in Stockholm, Sweden, from June 11 to 14, 2026.

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH

– Lorundrostat was associated with significant reductions in heart failure risk biomarkers in a proteomic analysis of data from participants with uncontrolled hypertension –